Achieve Life Sciences reports Q3 2023 net loss $7.1M; cash $20M; advances cytisinicline trials

ACHIEVE LIFE SCIENCES, INC.

2023-Q3 EPS reported -$1.26

Cash and restricted cash $20.0M as of Sep 30, 2023; net loss $7.1M in Q3 2023.
ORCA-2 Phase 3 smoking cessation results published in JAMA; cytisinicline showed significant efficacy.
Completed dosing of three NDA-supportive studies (QT, PK in smokers, renal impairment); data due early 2024.
Phase 2 ORCA-V1 results presented: 2.6-fold increase in vaping cessation odds vs placebo.
Shares outstanding: 21,165,760 as of Nov 9, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ACHIEVE LIFE SCIENCES, INC. reported third quarter 2023 results: net income Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively..

Period: third quarter 2023
Net income: Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively.
Result: reported results

Exact text from the filing

Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ACHIEVE LIFE SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-062005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.